NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer

Inclusion Criteria: * resectable adenocarcinoma of the pancreatic head (requiring duodeno-pancreatectomy) * T1-3, Nx, M0 (UICC 6th version, 2002) * infiltration of the portal vein (\<180°) is not an exclusion criterion * cytologic or histologic confirmation of adenocarcinoma * age \>18 years * written informed consent Exclusion Criteria: * contraindication for Whipple procedure * an infiltration \>180° of the portal vein * abutment of the tumor to the superior mesenteric artery * infiltration of the superior mesenteric artery or the celiac trunk * chronic neuropathy \> grade 2 * WHO performance score \>2 * uncorrectable cholestasis (bilirubin \> 100mmol/l despite drainage attempts for more than four weeks prior to inclusion) * female patients in child bearing age not using adequate contraception (oral or subcutaneous contraceptives, intrauterine pessars (IUP), condoms) * pregnant or lactating women * mental or organic disorders which could interfere with giving informed consent or receiving treatments * Second malignancy diagnosed within the past 5 years, except non-melanomatous skin cancer or non-invasive cervical cancer * percutaneous biopsy of the primary tumor